Lupin Receives European Commission Approval for Biosimilar Ranibizumab

Global pharma major Lupin Limited has received approval from the European Commission for its biosimilar ranibizumab, Ranluspec™. The biosimilar is for vials and pre-filled syringes and is used for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use. Lupin's biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany) and by two companies, Sandoz and Biogaran, in France.